Sagimet Biosciences Inc. (SGMT) Fair Value 2026

SGMT · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.4 /10

32 fundamental signals · 1 models active

Value Trap Risk

WARN (53/100)

Quick Summary — As of 2026-08-28, Sagimet Biosciences Inc. (SGMT) trades at $10.55. QOC: 4.4/10. Value Trap Risk: 53/100 (WARN). 1/13 models active.

Key Facts

Ticker
SGMT
Price
$10.55
Quality Score
4.4/10
Value Trap Risk
53/100
Models Active
1/13
Last Updated
Strength: 1 independent models provide multi-angle coverage
Risk: Value Trap score of 53 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give SGMT?

1 Intrinsic Value Models vs. Current Price ($10.55)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · Medium Conviction
 $0.21 -98.0%

All Models Active

All 1 models are displayed above.

What Is Sagimet Biosciences Inc. (SGMT) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Sagimet Biosciences Inc.'s intrinsic value is estimated at $0.21, suggesting the stock is overvalued at its current price of $10.55. With 1 out of 1 models flagging downside (-98.0% vs price), the market may be pricing in unsustainable growth.

What Do the Models Say About SGMT?

1 of 13 models are currently active for SGMT. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does SGMT Rank in Biotechnology?

Among 625 Biotechnology stocks, SGMT ranks #465 by Quality of Company score. CirclFi's QOC score of 4.4/10 evaluates 32 fundamental signals. A score of 4.4 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

As a biotech sector, Sagimet Biosciences Inc. operates in a sector where partnership revenue is a critical driver of valuation. Investors evaluating SGMT should weigh these sector-specific dynamics alongside our model-derived fair values.

Is SGMT a Value Trap?

CirclFi's Value Trap algorithm assigns SGMT a score of 53/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Sagimet Biosciences Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Sagimet Biosciences Inc.'s fundamental quality profile registers 4.4/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every SGMT valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across SGMT's 1 active models, average confidence is 49%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Sagimet Biosciences Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

ALLRAllarity Therapeutics, Inc.QOC 4.4ONCYOncolytics Biotech Inc.QOC 4.4ELVNEnliven Therapeutics, Inc.QOC 4.5VERUVeru Inc.QOC 4.4KPRXKiora Pharmaceuticals, Inc.QOC 4.5BZYRBurzynski Research Institute, Inc.QOC 4.4RADXRadiopharm Theranostics LimitedQOC 2.0ATNMActinium Pharmaceuticals, Inc.QOC 6.0IMMXImmix Biopharma, Inc.QOC 5.0EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: ALLR · ONCY · ELVN · VERU · KPRX · BZYR · RADX · ATNM · IMMX · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to SGMT?

5 companies across all industries closest to SGMT’s Quality of Company score of 4.4/10.

RAKRRainmaker Worldwide Inc.QOC 4.5MODDModular Medical, Inc.QOC 4.4ENRTEnertopia Corp.QOC 4.5SVMBJingbo Technology, Inc.QOC 4.4NVDANVIDIA CorporationQOC 10.0

Read investment analysis: RAKR · MODD · ENRT · SVMB · NVDA

Where Does SGMT Sit in CirclFi's Biotechnology Rankings?

SGMT is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Sagimet Biosciences Inc.’s Valuation?

What is Sagimet Biosciences Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Sagimet Biosciences Inc. (SGMT). The Quality of Company score is 4.4/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is SGMT overvalued or undervalued right now?

At $10.55, 0 of 1 active models suggest SGMT may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits Sagimet Biosciences Inc.'s business model in Biotechnology.

What does a Quality of Company score of 4.4 mean for SGMT?

Sagimet Biosciences Inc.'s QOC of 4.4/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on SGMT?

CirclFi analyzes SGMT with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is SGMT a value trap in 2026?

Sagimet Biosciences Inc.'s Value Trap score is 53/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Sagimet Biosciences Inc. (SGMT) a Quality of Company score of 4.4/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/SGMT/ · Methodology
Primary sources for this SGMT valuation
  • Financial statements: Sagimet Biosciences Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001400118) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for SGMT as of ; valuations recomputed .